Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s shares closed last Friday at $0.75. Leverage the ...

Pre-Market: 5:02:04 a.m. EST Loading Chart for MRSN ...

The Cagayan de Oro-based The Crusader and The Liceo U Student Press back their Camarines Sur counterpart, stressing the vital role of campus newspapers in amplifying student voices ...